Troglitazone, a peroxisome proliferator-activated receptor &gamma; ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 14

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

325

HTML

2892

Figures (1-7)

273

Sum=3490

Apr 14, 2008 (publication date) through Feb 8, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Apr 14, 2008; 14(14): 2168-2173
Published online Apr 14, 2008. doi: 10.3748/wjg.14.2168

Full Size Figure Download Figure

Figure 3 Cell cycle analysis by flow cytometry. A: Control cells; B: 20 &mgr;mol/L troglitazone; C: 30 &mgr;mol/L troglitazone.

Citation: Zhou YM, Wen YH, Kang XY, Qian HH, Yang JM, Yin ZF. Troglitazone, a peroxisome proliferator-activated receptor γ ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World J Gastroenterol 2008; 14(14): 2168-2173
URL: https://www.wjgnet.com/1007-9327/full/v14/i14/2168.htm
DOI: https://dx.doi.org/10.3748/wjg.14.2168